Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Long-Term Debt Repayments (2020 - 2022)

Theravance Biopharma (TBPH) has disclosed Long-Term Debt Repayments for 3 consecutive years, with -$168.4 million as the latest value for Q4 2022.

  • On a quarterly basis, Long-Term Debt Repayments changed N/A to -$168.4 million in Q4 2022 year-over-year; TTM through Dec 2022 was $231.6 million, a N/A change, with the full-year FY2022 number at $231.6 million, up 2058.48% from a year prior.
  • Long-Term Debt Repayments was -$168.4 million for Q4 2022 at Theravance Biopharma, down from $389.3 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $389.3 million in Q3 2022 to a low of -$168.4 million in Q4 2022.
  • A 3-year average of $93.4 million and a median of $5.7 million in 2021 define the central range for Long-Term Debt Repayments.
  • Biggest YoY gain for Long-Term Debt Repayments was 97.58% in 2021; the steepest drop was 97.58% in 2021.
  • Theravance Biopharma's Long-Term Debt Repayments stood at $235.3 million in 2020, then crashed by 97.86% to $5.0 million in 2021, then tumbled by 3446.44% to -$168.4 million in 2022.
  • Per Business Quant, the three most recent readings for TBPH's Long-Term Debt Repayments are -$168.4 million (Q4 2022), $389.3 million (Q3 2022), and $5.0 million (Q2 2021).